MX2015004821A - Metodos y composiciones para tratar condiciones dependientes de la progesterona. - Google Patents
Metodos y composiciones para tratar condiciones dependientes de la progesterona.Info
- Publication number
- MX2015004821A MX2015004821A MX2015004821A MX2015004821A MX2015004821A MX 2015004821 A MX2015004821 A MX 2015004821A MX 2015004821 A MX2015004821 A MX 2015004821A MX 2015004821 A MX2015004821 A MX 2015004821A MX 2015004821 A MX2015004821 A MX 2015004821A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treating
- dependent conditions
- conditions
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 229960003387 progesterone Drugs 0.000 title 1
- 239000000186 progesterone Substances 0.000 title 1
- 230000000708 anti-progestin effect Effects 0.000 abstract 2
- 239000003418 antiprogestin Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722095P | 2012-11-02 | 2012-11-02 | |
| PCT/US2013/066095 WO2014070517A1 (en) | 2012-11-02 | 2013-10-22 | Methods and compositions for treating progesterone-dependent conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015004821A true MX2015004821A (es) | 2015-08-14 |
Family
ID=49510593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004821A MX2015004821A (es) | 2012-11-02 | 2013-10-22 | Metodos y composiciones para tratar condiciones dependientes de la progesterona. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9545411B2 (enExample) |
| EP (1) | EP2914268B1 (enExample) |
| JP (2) | JP6343619B2 (enExample) |
| CN (1) | CN104755087A (enExample) |
| AU (1) | AU2013338305B2 (enExample) |
| CA (1) | CA2888377C (enExample) |
| ES (1) | ES2688821T3 (enExample) |
| HK (1) | HK1211852A1 (enExample) |
| IL (1) | IL238403B (enExample) |
| MX (1) | MX2015004821A (enExample) |
| WO (1) | WO2014070517A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42103A (fr) * | 2015-05-18 | 2018-03-28 | Bayer Pharma AG | Régime posologique à base de modulateur sélectif du récepteur de la progestérone (rpm) |
| US20190008804A1 (en) * | 2016-01-12 | 2019-01-10 | Repros Therapeutics Inc. | Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions |
| CN113905760A (zh) | 2019-02-28 | 2022-01-07 | 詹森生物科技公司 | 用于治疗化脓性汗腺炎的抗IL-α抗体 |
| CN115702023A (zh) | 2020-04-16 | 2023-02-14 | 詹森生物科技公司 | 化脓性汗腺炎的治疗 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| JPH0830004B2 (ja) | 1983-11-14 | 1996-03-27 | コロンビア ラボラトリーズ インコーポレイテッド | 生物接着性組成物およびそれにより治療する方法 |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| ATE235907T1 (de) | 1995-02-02 | 2003-04-15 | Schering Ag | Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
| ES2152671T3 (es) | 1996-05-01 | 2001-02-01 | Us Gov Health & Human Serv | Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| AU2805397A (en) | 1996-08-30 | 1998-03-19 | Population Council, Center For Biomedical Research, The | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| ATE396197T1 (de) | 2000-03-17 | 2008-06-15 | Us Gov Health & Human Serv | 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität |
| IN191020B (enExample) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| CA2423017C (en) | 2000-10-18 | 2009-01-06 | Bayer Schering Pharma Aktiengesellschaft | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| CN1289075C (zh) | 2001-07-09 | 2006-12-13 | 佐纳根有限公司 | 富含反式克罗米酚的克罗米酚组合物的用途 |
| JP4898431B2 (ja) | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| JP5017109B2 (ja) | 2004-07-09 | 2012-09-05 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | プロゲステロン受容体モジュレーターを含有する徐放性組成物 |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| NZ560551A (en) | 2005-03-22 | 2010-02-26 | Repros Therapeutics Inc | Dosing regimes for trans-clomiphene |
| CA2604218A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| US20090149434A1 (en) | 2005-09-29 | 2009-06-11 | Joseph Podolski | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| MY150763A (en) | 2006-10-24 | 2014-02-28 | Repros Therapeutics Inc | Compositions and methods for suppressing endometrial proliferation |
| EP2144601A4 (en) | 2007-04-05 | 2012-10-10 | Univ Kansas | RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE |
| SI2148681T1 (sl) | 2007-04-20 | 2016-07-29 | Preglem S.A. | Selektivni modulatorji progesterona v zdravljenju maternične krvavitve |
| US20110208118A1 (en) | 2007-09-20 | 2011-08-25 | Bio-Pro Medical Ltd. | Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and related disorders by mifepristone |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| US20130066302A1 (en) | 2009-09-29 | 2013-03-14 | MEDIMETRICS Personalized Drug Delivery B.V. | Intrauterine electronic capsule for administering a substance |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| DE202011110355U1 (de) * | 2011-03-09 | 2014-01-15 | Arstat, Inc. | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-10-22 US US14/440,023 patent/US9545411B2/en not_active Expired - Fee Related
- 2013-10-22 CN CN201380057256.XA patent/CN104755087A/zh active Pending
- 2013-10-22 MX MX2015004821A patent/MX2015004821A/es unknown
- 2013-10-22 WO PCT/US2013/066095 patent/WO2014070517A1/en not_active Ceased
- 2013-10-22 JP JP2015540700A patent/JP6343619B2/ja not_active Expired - Fee Related
- 2013-10-22 AU AU2013338305A patent/AU2013338305B2/en not_active Ceased
- 2013-10-22 HK HK15112776.8A patent/HK1211852A1/xx unknown
- 2013-10-22 CA CA2888377A patent/CA2888377C/en not_active Expired - Fee Related
- 2013-10-22 ES ES13783818.1T patent/ES2688821T3/es active Active
- 2013-10-22 EP EP13783818.1A patent/EP2914268B1/en active Active
-
2015
- 2015-04-21 IL IL238403A patent/IL238403B/en active IP Right Grant
-
2018
- 2018-01-25 JP JP2018010276A patent/JP2018062530A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2688821T3 (es) | 2018-11-07 |
| AU2013338305A1 (en) | 2015-05-14 |
| CA2888377A1 (en) | 2014-05-08 |
| WO2014070517A1 (en) | 2014-05-08 |
| IL238403B (en) | 2019-01-31 |
| EP2914268B1 (en) | 2018-07-04 |
| CA2888377C (en) | 2021-02-02 |
| US20150297612A1 (en) | 2015-10-22 |
| IL238403A0 (en) | 2015-06-30 |
| JP2015535282A (ja) | 2015-12-10 |
| JP6343619B2 (ja) | 2018-06-13 |
| US9545411B2 (en) | 2017-01-17 |
| AU2013338305B2 (en) | 2018-06-07 |
| CN104755087A (zh) | 2015-07-01 |
| EP2914268A1 (en) | 2015-09-09 |
| HK1211852A1 (en) | 2016-06-03 |
| JP2018062530A (ja) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015068A (es) | Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo ( bet ) y el uso de los mismos en el tratamiento de cancer. | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| IN2014KN00848A (enExample) | ||
| CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
| IN2015MN00478A (enExample) | ||
| MX2016007063A (es) | Peptidos terapeuticos. | |
| MX388221B (es) | ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2. | |
| SG10201408483QA (en) | Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc | |
| PH12015501997A1 (en) | Compositions and methods for diagnosis and treatment of hepatic cancers | |
| EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
| PH12013501176A1 (en) | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions | |
| MX2015016550A (es) | Antagonistas de imidazolil progesterona. | |
| IN2013MU03641A (enExample) | ||
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| PH12014502551B1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| CY1119470T1 (el) | Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη | |
| MX2013006732A (es) | 19-noresteroides novedosos y su uso para tratar condiciones que dependen de progesterona. | |
| IN2013MU01113A (enExample) | ||
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
| EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| IN2013MU02732A (enExample) | ||
| WO2014079931A8 (en) | Cd44v6-derived peptides for treating breast cancers | |
| IN2012DE00873A (enExample) | ||
| IN2013CH05770A (enExample) |